David Adlam

Showing 1-3 of 3 articles

Coronary interventions

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial

Serruys P, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C, Spitzer E, Walsh S, Adlam D, Hildick-Smith D, Édes I, van de Harst P, Krackhardt F, Tijssen J, Rademaker-Havinga T, Garg S, Steg P, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt F

December 20, 2019 | 10.4244/EIJ-D-19-00202

Coronary interventions

Long-term follow-up of spontaneous coronary artery dissection treated with bioresorbable scaffolds

Macaya F, Salinas P, Gonzalo N, Camacho-Freire SJ, Jackson R, Massot M, Ortas-Nadal MR, Sanchez Recalde A, Diaz-Fernandez J, Moreu J, Adlam D, Escaned J

January 18, 2019 | 10.4244/EIJ-D-18-00519

Editorial on: “Characteristics of extension and de novo recurrent spontaneous coronary artery dissection”

Adlam D, Wood A, Al-Hussaini A

December 8, 2017 | 10.4244/EIJV13I12A220

1

Latest news

A State-of-the Art and Mini Focus on Intracoronary OCT; Thrombectomy for Acute Ischaemic Stroke; and more…

Intracoronary OCT: State of the Art and Future Directions

Ziad A. Ali et al.

PCR Companion attending EuroPCR? Activate your free subscription!

Access the full Trials Book 2021

(Thanks to the support of Biotronik)

This Week's JAA's: ABSORB DAPT, OFR in predicting post-PCI FFR and more...

Joint EAPCI/ACVC expert consensus on pVADs

Alaide Chieffo et al.

New JAA's: Impact of HPR on clopidogrel monotherapy and more...

Valvular disease